The AES Corporation AES
14.87 USD -0.02 (-0.13%)
At closeNov 9, 2026, 4:16 AM EST
14.91 +0.04 +0.26%
Pre-market · Nov 9, 4:16 AM ET
14.87 Day range 14.93
13.28 52-week range 17.65
- YTD
- +3.70%
- 1 year
- +4.79%
News
benzinga.com AES Corp Says European Commission Unconditionally Approves Aes Merger On October 15, 2026; NYPSC Issues Ruling Requiring No Further Review For AES Merger On October 19, 2026 On October 15, 2026, the European Commission unconditionally approved the Merger under Council Regulation (EC) No. 139/2004 (as amended) (the "EU Merger Regulation Approval"). Additionally, on…stock.setn.com 雲商資本支出1.467兆美元 台股26強接單 全球AI發展邁入商業化應用，推論市場與自研ASIC晶片需求爆發，帶動北美四大雲端服務商資本支出持續飆升。台廠供應鏈如鴻海、廣達、奇鋐及台達電等業者，全面受惠於AI伺服器整機代工、液冷散熱升級與電源架構革命。隨著2027年IC載板產能將陷入嚴重供不應求 ...
- liderlegal.com Garrigues, Iberdrola, Gómez-Acebo & Pombo and Ecix shine at the Legal Leadership Awards 2026 Gericó Associates held its National Law Gala on November 5th, where the Legal Leadership Awards 2026 were presented—the first edition under its new name. The awards recognize firms, legal…
stocktitan.net CIDEB siRNA Normalizes Liver Fat and Improves Liver Injury Markers in MASLD Patients, as Highlighted at AASLD Regeneron Pharmaceuticals (NASDAQ: REGN) reported that a single CIDEBsiRNA dose reduced liver fat in a first-in-human trial in adults with fatty liver disease.The Phase 1/2 trial included 30 ...
marketscreener.com Regeneron Pharmaceuticals, Inc. Announces First-In-Human Trial Results For CIDEBsiRNA In MASLD Patients Regeneron Pharmaceuticals, Inc. announced the first results from a first-in-human trial that demonstrated a single subcutaneous dose of CIDEBsiRNA rapidly normalized liver fat and improved liver ...tw.stock.yahoo.com 12KW加速出貨，順達BBU營收看回升 MoneyDJ新聞 2026-11-09 09:58:06 邱建齊 ...
tw.stock.yahoo.com jpp Q3賺進半個股本；2027年看穩健成長 MoneyDJ新聞 2026-11-09 10:48:58 劉莞青 發佈jpp-KY(5284)第三季受惠伺服器周邊零組件訂單暢旺，大賺2.93億元、EPS ...
tw.stock.yahoo.com AES-KY明年看BBU營收持續正向，增速料續優LEV MoneyDJ新聞 2026-11-09 10:21:11 邱建齊 ...